All In Biotech

Drug Trial Radar · NCT06082635

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

A Multi-centered, Randomized, Open-label Phase III Study to Evaluate the Efficacy and Safety of TGRX-326 Comparing With Crizotinib in Patients of Advanced ALK-positive or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 321 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

321

Actual

Start

Dec 14, 2023

Primary completion

Apr 30, 2026

Study completion Nov 30, 2028

Sponsor

Lead sponsor
Shenzhen TargetRx Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Sun Yat-Sen University Cancer Center
First posted
Oct 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, open-label, Phase III clinical trial which compares the safety and efficacy of TGRX-326 with crizotinib in patients with ALK-positive advanced or metastatic NSCLC

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • TGRX-326Drug

    Subjects will be treated with the investigational drug TGRX-326 at 60 mg once a day in 28-day cycles

  • CrizotinibDrug

    Subjects will be treated with the control drug crizotinib at 250 mg twice a day in 28-day cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) by independent review committee (IRC)Time frame: Every 8 weeks between Cycle 1 and Cycle 17, and every 12 weeks from Cycle 17 and onwards (every cycle is 28 days); an average of 1.5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.